You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Baxter
Johnson and Johnson
Mallinckrodt
Harvard Business School

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AIN457

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for AIN457

Trial ID Title Status Sponsor Phase Summary
NCT00584740 Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease Terminated Novartis Pharmaceuticals Phase 2 This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.
NCT00669916 A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis Completed Novartis Pharmaceuticals Phase 1/Phase 2 This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study comparing 3 mg/kg of AIN457 to placebo. Subjects with a diagnosis of moderate to severe stable plaque psoriasis will be randomized to receive either AIN457 or placebo. AIN457 or placebo will be administered by single infusion at baseline and subjects will be observed for up to 26 weeks following the infusion.
NCT00669942 Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients Completed Novartis Pharmaceuticals Phase 1/Phase 2 Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as a single dose (intravenous infusion) in patients with active rheumatoid arthritis in combination with a stable dose of methotrexate. And to compare efficacy on the dose groups.
NCT00685399 Safety and Efficacy of AIN457 in Noninfectious Uveitis Completed Novartis Pharmaceuticals Phase 2 This study will test the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for AIN457

Condition Name

Condition Name for
Intervention Trials
Psoriatic Arthritis 5
Rheumatoid Arthritis 4
Psoriasis 3
Ankylosing Spondylitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Arthritis 13
Psoriasis 13
Arthritis, Psoriatic 9
Spondylitis, Ankylosing 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for AIN457

Trials by Country

Trials by Country for
Location Trials
United States 257
Japan 52
United Kingdom 36
Italy 34
Canada 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Texas 18
California 17
North Carolina 14
Arizona 12
South Carolina 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for AIN457

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 4 2
Phase 3 26
Phase 2 18
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 21
Not yet recruiting 13
Terminated 9
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for AIN457

Sponsor Name

Sponsor Name for
Sponsor Trials
Novartis Pharmaceuticals 50
Yanqiao Zhang 1
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 51
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Johnson and Johnson
Merck
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.